Mallinckrodt Pharmaceuticals plc is an Irish-American manufacturer of specialty pharmaceuticals (namely, adrenocorticotropic hormone), generic drugs and imaging agents. [2] In 2017, it had 5,500 employees and sales of $3.2 billion, of which $2.9 billion was from the U.S. healthcare system. [3] On August 1, 2025, it was announced that the firm had merged its operations with those of Endo. [4] Ireland’s Mallinckrodt will buy U.S. drugmaker Endo in a cash-and-stock deal valued at $6.7 billion. The companies said Thursday that Endo shareholders will receive a total of $80 million in cash and own nearly 50% of the combined company. Mallinckrodt shareholders will have a stake of slightly more than 50%. The companies plan to combine their generic pharmaceutical businesses and a sterile. /PRNewswire/ -- Mallinckrodt plc and Endo, Inc. today announced that they have completed their merger to create a global, scaled, diversified therapeutics. Mallinckrodt looks like it could join Purdue Pharma in reaching a settlement in its bankruptcy proceedings related to opioid litigation, after years of legal wrangling. The Ireland-headquartered. Mallinckrodt is a global specialty pharmaceutical business that develops, manufactures, markets and distributes specialty pharmaceutical products. Areas of focus include therapeutic drugs for autoimmune and rare disease specialty areas like neurology, rheumatology, nephrology and pulmonology; neonatal critical care respiratory therapies; and analgesics and hemostasis products. The company’s. Mallinckrodt Pharmaceuticals combined with Endo in 2025 to better serve customers and improve outcomes for the patients we support. From this union, we established two focused, standalone. The company is headquartered in St. Louis and boasts a portfolio of around 200 products across generics, API and sterile injectables following the Mallinckrodt-Endo fusion, according to the release. Mallinckrodt and Endo are merging to create a leading global therapeutics company with branded and generic products. Stay tuned for updates. Mallinckrodt plc ( Mallinckrodt ) today announced the completion of the planned spin-off of its Par Health generic pharmaceuticals and sterile injectables businesses. Moving ahead, Mallinckrodt. This site is an online medical resource intended to provide scientifically accurate, evidence-based, and balanced medical information on Mallinckrodt products. The information provided on this site and by Medical Information are not intended to provide medical advice or guidelines, but rather to empower healthcare providers, patients, and.